SMAD4 and neoplasm: SMAD4 was the predominant mutation in early stages (I–II) (56.0% vs. 26.5%, p = 0.021), while later stages (III–IV) showed significantly higher rates of KRAS mutations (100.0% vs. 75.8%, p = 0.001) compared to PHC at corresponding tumor stages [39].